Pre-made Certolizumab benchmark antibody ( Fab, anti-TNFA/TNF therapeutic antibody, Anti-DIF/TNFSF2/TNLG1F Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-100
Pre-Made Certolizumab biosimilar, Fab, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Certolizumab pegol, sold under the brand name Cimzia, is a biologic medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Certolizumab biosimilar, Fab, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||5wuv:HL/5wux:HL:AB:CD|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Approved||Ankylosing spondylitis;Crohn's disease;Plaque psoriasis;Psoriatic arthritis;Rheumatoid arthritis;Spondylitis;Non-radiographic axial spondyloarthritis|
|Conditions Active||Interstitial cystitis;Juvenile rheumatoid arthritis|
|Conditions Discontinued||Cognition disorders|